Increasing Thyromimetic Potency through Halogen Substitution.
ChemMedChem
; 11(21): 2459-2465, 2016 Nov 07.
Article
em En
| MEDLINE
| ID: mdl-27731931
Sobetirome is one of the most studied thyroid hormone receptorâ
ß (TRß)-selective thyromimetics in the field due to its excellent selectivity and potency. A small structural change-replacing the 3,5-dimethyl groups of sobetirome with either chlorine or bromine-produces significantly more potent compounds, both inâ
vitro and inâ
vivo. These halogenated compounds induce transactivation of a TRß-mediated cell-based reporter with an EC50 value comparable to that of T3, access the central nervous system (CNS) at levels similar to their parent, and activate an endogenous TR-regulated gene in the brain with an EC50 value roughly five-fold lower than that of sobetirome. Previous studies suggest that this apparent increase in affinity can be explained by halogen bonding between the ligand and a backbone carbonyl group in the receptor. This makes the new analogues potential candidates for treating CNS disorders that may respond favorably to thyroid-hormone-stimulated pathways.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Idioma:
En
Revista:
ChemMedChem
Ano de publicação:
2016
Tipo de documento:
Article